General Information of DTT (ID: TTOD7B3)

DTT Name Retinoic acid receptor (RAR) DTT Info
Gene Name RAR

Molecule-Related Drug & Molecule List

Molecule-Related Drug List
Molecule Type:
DTT
DTP
DME
Drug Status:
Discontinued Drug(s)
Approved Drug(s)
Clinical Trial Drug(s)
4 Approved Drug(s) Transported by This DTP
Drug Name Drug ID Indication ICD 11 Highest Status REF
Adapalene DMX2358 Acne vulgaris ED80 Approved [1]
Isotretinoin DM4QTBN Acne vulgaris ED80 Approved [2]
Tretinoin DM49DUI Acne vulgaris ED80 Approved [3]
Vitamin A DMJ2AH4 Night blindness 9D45 Approved [4]
------------------------------------------------------------------------------------
5 Clinical Trial Drug(s) Transported by This DTP
Drug Name Drug ID Indication ICD 11 Highest Status REF
13-cis-retinoic acid DMTZ1A5 Glioma 2A00.0 Phase 3 [5]
Fenretinide DMRD5SP Macular degeneration 9B78.3 Phase 3 [6]
Peretinoin DMESAZK Hepatocellular carcinoma 2C12.02 Phase 3 [7]
Velac Gel DMXHI89 Acne vulgaris ED80 Phase 3 [8]
Amsilarotene DMOB01U Solid tumour/cancer 2A00-2F9Z Phase 2 [9]
------------------------------------------------------------------------------------
5 Discontinued Drug(s) Transported by This DTP
Drug Name Drug ID Indication ICD 11 Highest Status REF
LAS-41001 DMXZ4BK Rosacea ED90.0 Discontinued in Preregistration [10]
IRX-4310 DMUYQH8 Psoriasis vulgaris EA90 Discontinued in Phase 3 [11]
BMY-30123 DMMJDYI Acne vulgaris ED80 Discontinued in Phase 2 [12]
LG-1550 DM8W31H Solid tumour/cancer 2A00-2F9Z Discontinued in Phase 2 [13]
MX-781 DMNZ356 Breast cancer 2C60-2C65 Terminated [14]
------------------------------------------------------------------------------------
Molecule Interaction Atlas

References

1 A review of adapalene in the treatment of acne vulgaris. J Adolesc Health. 2008 Nov;43(5):421-4.
2 Retinoid agonist isotretinoin ameliorates obstructive renal injury. J Urol. 2003 Oct;170(4 Pt 1):1398-402.
3 Retinoids--which dermatological indications will benefit in the near future Skin Pharmacol Appl Skin Physiol. 2001 Sep-Oct;14(5):303-15.
4 Vitamins and cofactors: highlights of ESBOC 2009. Nat Chem Biol. 2009 Aug;5(8):530-3.
5 13-cis retinoic acid exerts its specific activity on human sebocytes through selective intracellular isomerization to all-trans retinoic acid and binding to retinoid acid receptors. J Invest Dermatol. 2000 Aug;115(2):321-7.
6 National Cancer Institute Drug Dictionary (drug id 39582).
7 Peretinoin, an acyclic retinoid, improves the hepatic gene signature of chronic hepatitis C following curative therapy of hepatocellular carcinoma. BMC Cancer. 2013 Apr 15;13:191.
8 Chromosomal translocation t(15;17) in human acute promyelocytic leukemia fuses RAR alpha with a novel putative transcription factor, PML. Cell. 1991 Aug 23;66(4):663-74.
9 Initial clinical trial of oral TAC-101, a novel retinoic acid receptor-alpha selective retinoid, in patients with advanced cancer. J Clin Oncol. 2002 Aug 15;20(16):3522-32.
10 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800027956)
11 An antagonist of retinoic acid receptors more effectively inhibits growth of human prostate cancer cells than normal prostate epithelium. Br J Cancer. 2004 Aug 2;91(3):580-8.
12 The pharmacology of a novel topical retinoid, BMY 30123: comparison with tretinoin. J Pharm Pharmacol. 1992 May;44(5):379-86.
13 US patent application no. 2005,0014,729, Method for the treatment or prevention of dermatological disorders with a cyclooxygenase-2 inhibitor alone and in combination with a dermatological treatment agent and compositions therewith.
14 The retinoid antagonist MX781 induces clusterin expression in prostate cancer cells via heat shock factor-1 and activator protein-1 transcription factors. Cancer Res. 2004 Aug 15;64(16):5905-12.